Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: AnchorDx, Lucid Diagnostics, HTG Molecular Diagnostics

NEW YORK – AnchorDx said this week its UriFind test was awarded breakthrough device designation by the US Food and Drug Administration. The test leverages urine DNA methylation detection-based technology for the early detection of bladder cancer. According to Guangzhou, China-based AnchorDX, UriFind is as good as cytoscopy and better than exfoliative cytology and fluorescence in situ hybridization for detecting early and non-muscle invasive bladder cancer. 


PavMed said this week that its subsidiary Lucid Diagnostics has inked a deal with telemedicine company UpScriptHealth, in which UpScript will offer a Lucid-branded, web-based telemedicine platform to support the upcoming EsoGuard Telemedicine Program. The telemedicine platform will enable patients with chronic heartburn symptoms, who are at risk for esophageal precancer and cancer, to request a video evaluation by a physician, who then can refer them for testing with Lucid's EsoGuard Esophageal DNA Test, if necessary. Once the test results are available, the physician can use them in patient management decisions.

According to PavMed, EsoGuard is a next-generation sequencing-based DNA methylation test performed on esophageal cells to detect esophageal precancer in at-risk patients with gastroesophageal reflux disease. Esophageal cells are collected for testing using Lucid's EsoCheck Cell Collection Device. Lucid is launching a network of test centers, initially in the Phoenix area, where patients can undergo EsoGuard testing. 


HTG Molecular Diagnostics said this week that it has created a new business unit called HTG Therapeutics, which will use the HTG EdgeSeq platform to develop early-stage drug candidates. The new business unit is a direct result of the development of HTG's nearly 20,000-gene mRNA panel (the HTG Transcriptome Panel) that the company expects to commercially release in August and is currently in the hands of early-access users. HTG said it will use the panel to profile RNA modifications early in the drug-discovery process to help generate lead compounds faster and with superior efficacy and toxicity profiles. The company will initially focus on identifying development candidates targeting RNA or RNA-modifying proteins, which could be relevant in areas such as oncology, immunology, transplant, diabetes, and rare disease. HTG President and CEO John Lubniewski noted in a statement that the company will continue to invest in its existing life science tools and diagnostics business, including HTG EdgeSeq instruments, RUO panels, and VERI/O lab service offerings. 


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.